ASH 2023 | Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, speaks on long noncoding RNAs (lncRNAs), which have been identified as potential therapeutic targets in multiple myeloma (MM) using CRISPR-Cas13 based functional transcriptomics. Screening of 6000 lncRNAs revealed 101 involved in myeloma cell survival, which will now be investigated as potential targets for future therapies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Bristol Myers Squibb, GlaxoSmithKline, AbbVie, Adaptive Biotechnologies, Janssen, Karyopharm, Legend, Novartis, OncoPep, Pfizer, Takeda
Current holder of stock options: Pfizer
